title: Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer.
abstract: Immune evasion is recognized as a key strategy for cancer survival and progression. With increased understanding of immune escape mechanisms, the development of immunotherapies to restore anti-tumor immune responses has flourished. Immuno-oncology (I-O) agents targeting checkpoints in the immune regulation cascade currently form the mainstay of approaches of cancer immunotherapy. Since initial success in melanoma, evidence for the notable effects of the I-O modality has been expanding, with numerous clinical studies underway or completed in a variety of solid tumors, including non-small cell lung cancer. This review highlights the rationale and potential role of immunotherapy in non-small cell lung cancer management, with a focus on immune checkpoint inhibitors. We also discuss the potential for I-O-based combination therapy.
authors.affiliation: LungenClinic Grosshansdorf, Department of Thoracic Oncology, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Woehrendamm 80, 22927, Grosshansdorf, Germany.
authors.forename: David
authors.initials: D
authors.lastname: Heigener
authors.forename: Martin
authors.initials: M
authors.lastname: Reck
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D016190:Carboplatin; D017239:Paclitaxel
keywords: cytotoxic T-lymphocyte-associated antigen 4; immune checkpoint inhibitors; immunotherapy; ipilimumab; lung cancer; nivolumab; non-small-cell lung cancer; programmed cell death protein 1